Neurological immune-related adverse events in checkpoint Inhibitor therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00019080

Enrollment

Registered

2019-11-13

Start date

2017-09-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurological (immune-related) adverse Events in checkpoint inhibitor therapy

Interventions

Group 1: Patients with checkpoint inhibitor therapy are regualry (every 8-12 weeks) observed and interviewed, examined and undertake electrophysical studies after enrollment and after 12 months to id

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. patient's consent 2. Age above 18 years 3. sufficient knowledge of German language 4. diagnosis of metastatic melanoma 5. checkpoint Inhibitor therapy

Exclusion criteria

Exclusion criteria: 1. restricted legal capacity

Design outcomes

Primary

Measure	Time frame
occurrence of neurological side effects/ neurological immune related adverse events	—

Countries

Germany

Contacts

Public ContactTim Hagenacker

Klinik für NeurologieUniversitätsklinikum Essen

tim.hagenacker@uk-essen.de+492017236513

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026